Campylobacter is a major foodborne pathogen in humans and a significant cause of abortion in sheep. Although ruminants are increasingly recognized as important reservoirs for Campylobacter, limited information is available about the molecular epidemiology and antimicrobial resistance (AMR) profiles of sheep Campylobacter. Here we describe a two-trial study that examined Campylobacter profiles in sheep and determined whether in-feed tetracycline influenced the distribution and AMR profiles of Campylobacter. Each trial involved 80 commercial sheep naturally infected with Campylobacter, 40 of which were medicated with tetracycline in feed, while the other 40 received feed without antibiotics. Fecal and bile samples were collected for the isolation of Campylobacter. The bacterial isolates were analyzed for antimicrobial susceptibility and genotypes. The results revealed that 87.0% and 61.3% of the fecal and bile samples were positive for Campylobacter (C. jejuni and C. coli), with no significant differences between the medicated and nonmedicated groups. All but one of the tested Campylobacter isolates were resistant to tetracycline. Although fluoroquinolone (FQ) resistance remained low in C. jejuni (1.7%), 95.0% of the C. coli isolates were resistant to FQ. Genotyping revealed that C. jejuni ST2862 and C. coli ST902 were the predominant genotypes in the sheep. Feed medication with tetracycline did not affect the overall prevalence, species distribution and AMR profiles of Campylobacter, but increased the total Campylobacter counts in bile and gallbladder. These findings identify predominant Campylobacter clones, reveal the high prevalence of FQ-resistant C. coli, and provide new insights into the epidemiology of Campylobacter in sheep.
4 clinical conditions, especially in young, elderly, or immunocompromised patients (5). However, 69 antimicrobial resistance in Campylobacter is increasingly prevalent and has become a major 70 public health concern in both developed and developing counties (6, 7) . Of particular concern is 71 the rising resistance to fluoroquinolone (FQ) and macrolide antibiotics, which are clinically 72 important for the treatment of Campylobacter induced diarrhea in humans, but in some cases, 73 tetracyclines and gentamicin are also used to treat systemic infection caused by Campylobacter 74 (6, 8, 9) . 75
Food-producing animals are important reservoirs for Campylobacter (10). Epidemiologically, 76 poultry meat is considered the major source of infection for human campylobacteriosis (11). C. 77 jejuni and C. coli frequently colonize the intestines of many species of poultry, especially 78 commercial chickens and turkeys, usually as part of the normal microbial flora without causing 79 clinical disease (12) . Recently, the role of ruminants (cattle and sheep) in Campylobacter 80 ecology has been increasingly recognized in different countries (13) (14) (15) (16) (17) . Ruminant 81
Campylobacter can be transmitted to humans via contaminated milk and water, environmental 82 contamination or direct contact with animals (18). Source attribution studies indicate that 83 ruminant Campylobacter is a significant source of infection for human campylobacteriosis (19-84 21) . 85
Typically, Campylobacter colonizes in the intestinal tract in animals, but it may also 86 5 24). Previous survey of healthy sheep in a slaughterhouse revealed genetically diverse C. jejuni 92 strains (including clone SA) present in the intestinal tract and gallbladder (25) . Despite the fact 93 that ruminants are increasingly recognized as important reservoirs for Campylobacter, limited 94 information is available about the molecular epidemiology and antimicrobial resistance profiles 95 of sheep Campylobacter in the United States. 96 For the control of abortion and other diseases, the tetracycline class of antibiotics is 97 commonly used in the U.S., and it is the only class of antibiotics approved for prevention and 98 control of sheep abortion associated with Campylobacter (23). However, whether the 99 administration of tetracycline in feed impacts the prevalence of Campylobacter in sheep is not 100 known. Previously, it was shown that sheep harbored diverse strains of C. jejuni that were 101 commonly resistant to tetracycline; however, resistance to FQ was seldomly detected (25) . 102
Recently, FQ resistance in cattle Campylobacter isolates has increased substantially in the U.S. 103 (15, (26) (27) (28) . However, detection of FQ resistance in sheep Campylobacter isolates is still limited. 104
To address these knowledge gaps, we collected samples and isolated Campylobacter from 105 controlled treatment (feed medication with tetracycline) studies using sheep that were derived 106 from commercial operations and were naturally infected by Campylobacter. The goals were to 107 examine the extent of FQ resistance in sheep Campylobacter and determine the effect of in-feed 108 tetracycline on the prevalence, species distribution, and antimicrobial resistance profiles of 109
Campylobacter in sheep. 110
Materials and Methods 111
Sample collection and Campylobacter isolation 112 6 commercial farms and then housed in the laboratory animal facility at Iowa State University 115 during the treatment study. Trial 1 was conducted using animals from farm 1, while trial 2 was 116 performed using animals from Farm 2. The two farms are in the Midwest region and are 117 geographically separated by approximately 86 miles. The ages of the sheep at enrolment varied, 118 but all were spring-born feeder lambs and approximately two months old. Both source farms 119 raise sheep in a semi-intensive management program with outdoor access. Treatment of sheep 120 with FQ antibiotics is expressly prohibited in the U.S. and there was no history of use of these 121 antibiotics on these farms. 122
In each trial, the animals were randomly assigned into the feed medicated and non-medicated 123 groups. Chlortetracycline (Aureomycin, Zoetis) was used for the feed medication, and the 124 medication was conducted to determine the effect of the antibiotic on prevention and control of 125 bacterial pneumonia in feedlot lambs. The antibiotic was fed extra-label (350 mg/hd/d; 160 126 mg/kg body weight or 160 ppm in feed) in accordance with the FDA/CVM's Guidance 615.115. 127 Regardless of the feed medication, clinically sick animals (19 in each group for trial 1; 17 and 128 18, respectively, for trail 2) received a chlortetracycline injection (9 mg/lb) and the injection 129 repeated once in 72 hr if needed. The treated sheep remained in their respective groups. 130 7 CO2). Up to three Campylobacter-like colonies from each sample were subcultured onto MH 137 agar plates and the pure cultures were stored in glycerol stocks at −80 °C. 138
Enumeration of Campylobacter in bile and gallbladder mucosa 139
In addition to isolation of Campylobacter from individual bile samples as described above, 140
we also determined the total Campylobacter colony forming units (CFUs) in bile and gallbladder 141 mucosa. For this purpose, bile and gallbladder samples were randomly collected from sheep at 142 necropsy in the two trials. In total, 37 and 35 bile/gallbladder mucosal samples were selected in 143 the two trials from the feed non-medicated and feed medicated groups, respectively. For each 144 group, the sheep were housed in 4 separate pens and the collected bile from each gallbladder (5-145 15 ml) was pooled based on treatment group and pen number. In total, 4 pools were obtained per 146 group in each trial. For collection of gallbladder mucosal samples, 5 ml of PBS was used to wash 147 any residual bile off each gallbladder mucosa. Then, a sterile razor blade was used to scrape 148 mucosa from each gallbladder onto a bile-free weigh boat. Next, the blade was washed with PBS 149 to rinse any mucosa on the blade onto the weigh boat, which then was rinsed with roughly 2 ml 150 of PBS, and the collected gallbladder mucosa was decanted into a 15 ml conical tube. The final 151 volume was adjusted to 3 ml, and the 15 ml conical tube was vortexed vigorously prior to culture 152 for Campylobacter. 153
For both the bile and gallbladder mucosal samples, a ten-fold dilution series was performed 154 using 1.5 ml snap cap tubes filled with 900 μl of MH broth. Each dilution was spread onto MH 155 agar plates containing selective supplement (SR084E; Oxoid) and standard culture conditions for 156
Campylobacter were utilized as for the fecal samples (described above). After culturing, the 8 CFU/mL of bile or gallbladder mucosal suspension. All of the 16 pooled bile samples 160 demonstrated visually pure growth of Campylobacter sp. and were utilized in the final 161 calculations. For the gallbladder mucosal samples, 4 in the non-medicated group and 9 in the 162 medicated group were not usable because of high background bacterial contamination after 163 culturing. The remaining plates were visually determined to have pure growth of Campylobacter 164 sp. and thus were used in the final calculations. In total, Campylobacter CFU counts were 165 obtained from 33 and 26 gallbladder mucosal samples in the non-medicated and medicated 166 groups, respectively. Representative colonies from each group were selected and subjected to 167 species confirmation and identification (see below). 168
Bacterial species identification 169
Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry 170 (Bruker) was used for bacterial species identification. All isolates were identified to the species 171 level. Sample preparation and analysis were done as described previously (29) . Mass spectra 172 were acquired and analyzed using a microflex LT mass spectrometer (Bruker Daltonics) in 173 combination with research-use-only version of the MALDI Biotyper Compass software 4.1 and 174 the reference database MBT 7311 MSP Library (#1829023) at Iowa State University. Data were 175 interpreted in accordance with the manufacturer's (Bruker Daltonics) standard criteria: a) high-176 confidence identification when the score was between 2.00 and 3.00, b) low-confidence 177 identification when the score was between 1.70 and 1.99, and c) no organism identification 178 possible when the score was 1.69 and lower. 179 C. jejuni Clone SA detection 180 PCR was used for identifying C. jejuni clone SA. DNA template was extracted from 181
Campylobacter colonies using single-cell lysis buffer (30). Primers specific for C. jejuni clone 182 9 SA were designed as described previously (31 following the CDC's standardized PulseNet protocol for Campylobacter with minor 208 modifications (23). Briefly, fresh cultures of Campylobacter were embedded in 1% Seakem Gold 209 agarose (Fisher Scientific, Fair Lawn, NJ) and lysed with proteinase K for 30 minutes at 50 °C in 210 a water bath shaker. The gel plugs were digested with KpnI for 4 h at 37 °C. Digested plugs were 211 embedded into 1% agarose and separated by electrophoresis in 0.5 × TBE buffer (Promega) at 14 212 °C for 18 h using a Chef Mapper electrophoresis system (Bio-Rad, Hercules, CA). The gels were 213 stained with ethidium bromide for 30 min and then photographed using a digital imager (Alpha 214 Innotech, Santa, Clara, CA). The PFGE patterns were analyzed by the GelCompare II v.6.5 215 software (Applied Maths, Kortrijk, Belgium) using Dice similarity coefficient and unweighted-216 pair group method with arithmetic averages (UPGMA) with 0.5% optimization and 1.5% 217 position tolerance. Lambda DNA ladder (Bio-Rad) was used as the molecular size marker. PFGE 218 patterns with ≥90% similarity was defined as a cluster. 219
To further confirm the genetic diversity of the isolates, MLST was performed for selected 220 representative isolates of different PFGE patterns as described previously (35) In Campylobacter, FQ resistance is conferred by point mutations in the gyrA gene in 231 conjunction with the CmeABC efflux pump (37). To confirm the mechanism of FQ resistance in 232 this study, four FQ R C. jejuni isolates and eight FQ R C. coli isolates of different PFGE and 233 MLST types were selected for determination of the point mutations in the quinolone resistance 234 determining region (QRDR) of gyrA. The primers GyrAF1 (5′-CAACTGGTTCTAGCCTTTTG-235
3) and GyrAR1 (5-AATTTCACTCATAGCCTCACG-3) were used for C. jejuni isolates, while 236
GyrAF2 (5-TTATTTAGATTATTCTATGAGCGT-3) and GyrAR2 (5-237 CTTGAGTTCGATTACAACAC-3) were used for C. coli isolates as described previously (15). 238
All PCR products were purified using the QIAquick® PCR purification kit (QIAGEN, Hilden, 239 Germany) and then sequenced at the DNA Core Facility of Iowa State University using an 240
Applied Biosystems 3730xl DNA Analyzer. 241
Statistical analysis 242
Chi-square test and Fisher's exact test were used to compare the prevalence and the 243 antimicrobial resistance rates of the Campylobacter isolates from different samples (fecal and 244 bile samples) and different groups (feed non-medicated and medicated groups). Unpaired t-test 245 was used to compare the average Campylobacter CFU/ml results from the bile and gallbladder 246 mucosal samples between the non-medicated and medicated groups in two trials. The data was 247 analyzed using GraphPad (Prism) . P values less than 0.05 were deemed to be statistically 248 (96/98) were C. jejuni, and 2.0% (2/98) were C. coli. The two C. coli isolates from bile were 260 both isolated from the feed medicated group in Trial 2 (Table 2) . Again, there was no significant 261 difference (P > 0.05) between the groups in the prevalence of either C. jejuni (100% vs. 95.8%) 262 or C. coli (0% vs. 4.2%). These results indicate that the in-feed tetracycline medication did not 263 affect the overall prevalence of Campylobacter in fecal and bile samples. 264
Statistically, the overall Campylobacter prevalence was higher in fecal samples than in bile 265 samples (87.0% vs. 61.3%, P < 0.05). However, the proportion of C. jejuni was significantly (P 266 < 0.05) lower in feces than in bile (68.6% vs. 98.0%), while the proportion of C. coli was higher 267 in feces than in bile (37.4% vs. 2.0%). Detailed information about the prevalence of 268
Campylobacter and the distribution of C. jejuni and C. coli is summarized in Tables 1 and 2 For the tested fecal C. jejuni isolates (n=236), all (100%) were resistant to tetracycline, but 286 the resistance rates to ciprofloxacin and nalidixic acid were low, at 1.7% (4/236) and 3.0% 287 (7/236), respectively. All four ciprofloxacin-resistant (CIP R ) C. jejuni isolates were derived from 288 Trial 2. One C. jejuni isolate from the non-medicated group in Trial 1 showed resistance to 289 gentamicin. The fecal C. coli isolates also showed a high resistance rate to tetracycline (99.0%; 290 100/101), with only one sensitive to this antibiotic. In contrast to C. jejuni, the C. coli isolates 291 were highly resistant to ciprofloxacin (95.0%; 96/101) and nalidixic acid (95.0%; 96/101). 292
Resistance to the other five antibiotics were not observed. The key MIC results are shown in 293 For the isolates from bile samples, all tested C. jejuni were resistant to tetracycline (100.0%, 296 96/96), but susceptible to other antibiotics, while the two C. coli isolates were resistant to 297 tetracycline, ciprofloxacin and nalidixic acid. None of the bile C. jejuni or C. coli isolates 298 showed resistance to gentamicin, azithromycin, erythromycin, florfenicol, telithromycin or 299 clindamycin. 300
Notably, the CIP resistance rate (95.0%) in C. coli is significantly (P < 0.05) higher than in 301 C. jejuni (1.7%) for the fecal samples. There is no significant difference (P > 0.05) in the overall 302 antimicrobial susceptibility profiles as tested in this study between fecal and bile C. jejuni. The 303 two C. coli isolates from bile samples also showed similar resistance patterns to the C. coli 304 isolates from feces. In addition, there was also no significant difference (P > 0.05) in the 305 antimicrobial resistance rates of C. jejuni and C. coli between the feed non-medicated and feed 306 medicated groups. 307
Genetic diversity of the Campylobacter isolates from sheep 308
In total, 24 C. coli and 39 C. jejuni isolates were selected for PFGE analysis. The twenty-four 309 C. coli consisted of twelve CIP R C. coli from feces (one representative isolate for each group and 310 each sampling time in the two trials), the two CIP R C. coli isolates from bile, the five CIP S fecal 311 C. coli, the TET susceptible C. coli and the other four fecal C. coli (isolated from the same sheep 312 with the two CIP R C. coli isolates from bile). The 24 C. coli isolates were grouped into three 313 separate clusters, with the vast majority of isolates (75.0%, 18/24) grouped into type Ⅲ (Figure  314 2). The five CIP S C. coli isolates were all in type Ⅰ, and type Ⅱ included one CIP R C. coli from 315 feces. The predominated cluster (type Ⅲ) consisted of 18 CIP R C. coli, among which 16 were 316 from fecal samples (including one TET susceptible isolate and 4 from the same sheep where the 317 two CIP R bile isolates were obtained) and two from bile samples (Figure 2 ). MLST analysis 318 on April 2, 2019 by guest http://aem.asm.org/ Downloaded from 15 showed that the C. coli isolates grouped in type Ⅰ, Ⅱ, Ⅲ belong to ST827, ST1068 and ST902, 319 respectively (Figure 2) , consistent with the classifications using PFGE. Thus, ST902 was the 320 most prevalent ST type in the sheep C. coli analyzed in this study. Interestingly, the CIP R bile 321 and fecal isolates from the same sheep shared the same PFGE type (III) and MLST type 322 (ST902), indicating the bile and fecal isolates are genetically related. 323
The 39 C. jejuni included twelve CIP S C. jejuni from bile (three representative isolates for 324 each group in two trials), the four CIP R C. jejuni from feces, the three CIP S fecal C. jejuni 325 (isolated from the same sheep with the CIP R isolates), twenty CIP S fecal C. jejuni isolates (from 326 different sheep that CIP R isolates were isolated, representative isolates from each group and each 327 sampling time in two trials, and including ten selected fecal C. jejuni isolated from the same 328 sheep with the six bile C. jejuni isolates). The 39 C. jejuni isolates were clustered into five 329 different clusters (Figure 3) , apart from four isolates that were non-typeable by PFGE because 330 they were not digestible by KpnI. The four non-typeable isolates included one CIP S bile isolate 331 and three selected CIP S fecal isolates from the same three sheep with bile isolates. Type A is the 332 predominant genotype and accounted for 69.2% (27/39) of the analyzed isolates. This 333 predominant cluster include both CIP R and CIP S C. jejuni isolated from fecal and bile samples. 334
MLST results indicated that all but two C. jejuni isolates in type A belonged to ST2862 (Figure  335 2). One of the two non-ST2862 isolates was a CIP R C. jejuni (ID: 0993), which showed only one 336 base difference in gltA with ST2862. After submitting the sequence to the MLST database, the 337 new gltA allele was assigned to gltA586 (in comparison it is gltA2 in ST2862) and the isolate was 338 assigned a new ST type ST9380. The other non-ST2862 isolate was also a new ST type 339 (ST9379) and was a bile isolate (ID: 292). The detailed information of MLST profiles in the two 340 isolates were presented in Table S2 . The other four PFGE patterns, types B, C, D and E, 341 on April 2, 2019 by guest http://aem.asm.org/ Downloaded from 16 consisted of 8 C. jejuni isolates. Type B belonged to ST982, while types C, D, and E all 342 belonged to ST52 (Figure 3 ). For the selected bile and fecal C. jejuni isolates from the same 343 sheep, the situation was more diverse comparing with the C. coli isolates (Figure 3 ). Bile and 344 fecal isolates from each of the animals with an ID number 898, 346 and 604 shared the same 345 PFGE and MLST profiles, while the bile and fecal isolates from other three animals were of 346 different PFGE or MLST types (ID292, the same PFGE with different ST types; ID961, different 347 PFGE types but with the same ST type; ID610, different PFGE types with different ST types). Results from this study revealed high prevalence of TET-resistant Campylobacter spp. and 361 CIP R C. coli in sheep derived from two commercial farms. These animals were naturally infected 362 and already carried antibiotic-resistant Campylobacter on the day of arrival (Tables 1, 2, and 3) . 363 Subsequent treatment with in-feed tetracycline in a research setting did not affect the overall 364 on April 2, 2019 by guest http://aem.asm.org/ Downloaded from prevalence, antimicrobial susceptibility profiles, and species distribution of Campylobacter as 365 there were no statistically significant differences (p > 0.05) between the feed medicated and non-366 medicated groups. However, the quantitative CFU counts in bile and gallbladder mucosa 367 collected at the end of the trials revealed higher total CFUs in the medicated group than the non-368 medicated group (P < 0.05), suggesting that tetracycline treatment may promote Campylobacter 369 colonization in gallbladder. The exact reason for this effect is unknown, but it is known that 370 tetracyclines undergo significant enterohepatic circulation, resulting in significant concentration 371 of tetracyclines in bile, which may inhibit competitive bacterial organisms and confer a 372 colonization advantage for tetracycline-resistant Campylobacter. Since similar numbers of 373 animals received therapeutic treatment in both groups, it is likely that the effect is attributable to 374 in-feed use of tetracycline. Regardless of the reasons, the enhanced colonization of gallbladder 375 may give Campylobacter an advantage in the spread to other organs or dissemination back to the 376 intestinal tract. 377
In fecal samples, C. jejuni accounted for 68.6% of the total isolates (Table 1) , while in bile 378 samples the isolates were almost exclusively C. jejuni (98.0%), suggesting that C. jejuni has a 379 higher tropism to bile or a higher ability to reach to and adapt within the gallbladder. Previous 380 studies observed similar prevalence between C. jejuni and C. coli in sheep gallbladders (38, 39) , 381 however, these previous studies were conducted in a different country and it is possible that 382 differences in sheep production practices or genetic variability of Campylobacter strains may 383 influence gallbladder colonization by the organism. Bile is harmful to bacteria, however, 384
Campylobacter utilizes the multidrug efflux pump CmeABC for bile resistance (40-43). The 385 exact reason for the predominance of C. jejuni in gallbladder as observed in this study is 386 unknown and remains to be investigated in future studies. Interestingly, C. jejuni clone SA was 387 on April 2, 2019 by guest http://aem.asm.org/ Downloaded from 18 not detected in the sheep examined in this study. This clone is a predominant cause of 388
Campylobacter-associated ovine abortions and is also distributed in feedlot and dairy cattle in 389 the U.S. (23, 44) . A recent study also reported identification of Clone SA in Grenada (45). The 390 lack of clone SA detection in this study is not entirely surprising as we have previously found 391 that the distribution of clone SA is highly variable from farm to farm (25). Thus, it was likely 392 that the two farms where the sheep were derived from did not harbor this particular C. jejuni 393 strain. 394
Except for FQs and tetracycline, the Campylobacter isolates examined in this study were 395 generally susceptible to other tested antimicrobials (Table 3 ). All but one of the tested 396
Campylobacter isolates from fecal and bile samples were resistant to tetracycline. This finding 397 further strengthens the result from our previous study on Campylobacter carriage in sheep 398 slaughterhouse, which revealed the resistance rate to tetracycline was already 83.3% (25). In this 399 study, the in-feed tetracycline medication did not further influence the prevalence of tetracycline-400 resistant Campylobacter due to the fact that tetracycline resistance in the sheep was already very 401 high (virtually 100%) at the beginning of the treatment. Thus, the result should be interpreted 402 precautiously. Given the high prevalence of tetracycline-resistant Campylobacter on sheep farms 403 in the U.S., the use of tetracycline as a mean to control Campylobacter-induced sheep abortion 404 would have a limited impact. In fact, tetracycline medication may have facilitated the persistence 405 of tetracycline-resistant Campylobacter on sheep farms. Results from this study further underline 406 the need for improved tetracycline stewardship in sheep to reduce the prevalence of tetracycline-407 resistant Campylobacter. 408 A significant finding of this work is the detected high prevalence of CIP R C. coli (95%), 409 while CIP resistance in the sheep C. jejuni isolates remained low (1.7%) ( Table 3 ). The 410 on April 2, 2019 by guest http://aem.asm.org/ Downloaded from 19 difference between C. coli and C. jejuni is unlikely due to variation in their susceptibility to 411 fluoroquinolones as CIP R C. jejuni is also common in other animal species (6, 7) . The high-level 412 prevalence of CIP R C. coli in sheep was unexpected as this class of antibiotics is not used in 413
sheep production in the United States. A recent study on cattle Campylobacter reported CIP 414 resistance rates of 35.4% in C. jejuni and 77.3% in C. coli (15) . This could be explained by the 415 fact that FQ antibiotics are labeled for treatment of respiratory disease in cattle in the U.S. The 416 reason for the detected high incidence of CIP R C. coli in sheep in this study is unknown, but 417 there is a possibility of transmission of CIP R Campylobacter from cattle to sheep. Although the 418 sampled sheep farms were not adjacent to other animal species, they could get Campylobacter 419 through birds, flies, or other transmission vehicles. However, if this were the sole case, we would 420 have also observed an increased prevalence of CIP R C. jejuni in sheep as it is also common in 421 cattle. It is possible that the CIP R C. coli strains were introduced to sheep by chance and 422 something on these farms favored the selection of CIP R C. coli, contributing to its overall high 423 prevalence in sheep. It should be pointed out that fluoroquinolones are also approved for use in 424 swine and were used in poultry prior to 2005 in the U.S. Thus, the possibility that sheep acquired 425 CIP R C. coli from other animal species rather than cattle can't be totally excluded. 426
To determine the genetic relatedness of the Campylobacter isolates, we conducted PFGE and 427
MLST analyses, which are commonly used for genotyping of Campylobacter (20, (46) (47) (48) . PFGE 428 typing of 24 representative C. coli revealed a limited number of types and that the majority 429 (18/24) of the CIP R C. coli isolates were grouped into a single type (type Ⅲ; Figure 2 ), which 430 was confirmed by MLST to be a single ST (ST902). It is worthwhile to note that type Ⅲ 431 included isolates from different and geographically distant farms and from different sampling 432 times, suggesting that this genotype is stable and is prevalent on different sheep farms. Also, bile 433 on April 2, 2019 by guest http://aem.asm.org/ Downloaded from 20 and fecal isolates from the same sheep shared the same PFGE type and ST type. The other two 434 PFGE types belonged to ST827 (type Ⅰ) and ST1068 (type Ⅱ). C. coli ST827 has been previously 435 reported, sometimes to be the most common ST in both sheep and cattle (49, 50) , while ST1068 436 is more often found in cattle (15, 50, 51) . Moreover, ST1068 was also identified among swine C. 437 coli isolates, sometimes to be the most predominant ST type (51) (52) (53) . In addition, the three 438 identified STs (ST902, ST827 and ST1068) all belong to the ST-828 complex (Figure 2) . 439
Although the specific prevalent ST types vary in different species, C. coli isolates of ST-828 440 complex, the most prevalent CC (clonal complex) for C. coli, have been frequently reported in 441 published studies from different countries and different sources, including poultry, cattle, sheep, 442 swine and even humans (15, (54) (55) (56) (57) . Our results confirmed the prevalence of this CC and the 443 existence of specific endemic ST type among animals in different regions. 444
The 39 representative C. jejuni isolates examined by PFGE typing in this study, they were 445 grouped into five clusters (Figure 3) , with the exception of four that were not typeable by PFGE 446 because KpnI failed to digest appropriately. Similar to the C. coli result, the majority (27/39) of 447 the tested C. jejuni isolates was grouped into one cluster (type A), which was confirmed by 448 MLST to be a single ST (ST2862) except for two isolates, suggesting it was the predominant C. 449 jejuni clone in sheep. This clone included both CIP S and CIP R C. jejuni isolated from both fecal 450 and bile samples that were collected from different farms (trials 1 and 2) and different sampling 451 times (Figure 3 ), indicating this genotype was commonly disseminated in sheep. The other four 452 PFGE types belonged to ST982 (type B) and ST52 (types C, D and E). ST982 accounted for 453 20.8% (10/48) of the C. jejuni isolates in a previous study involving a lamb slaughterhouse and 454 was also reported in cattle (15, 25, 58) . ST-52 was reported sporadically in C. jejuni from 455 21 different countries and sources, including ruminants (45-47, 57, 59, 60) . Both ST2862 and 456 ST982, belong to CC21, which is the most prevalent CC in C. jejuni. 457
To examine the possible transmission of Campylobacter between sheep and cattle, we 458 selected some cattle Campylobacter isolates identified in our previous study (15) to compare 459 with the sheep Campylobacter isolates identified in this study. The PFGE and MLST results 460 revealed that ST902 (the predominant C. coli genotype in sheep identified in this study) with the 461 same PFGE pattern was also found in the cattle C. coli (Figure S1a ), although the predominant 462 ST was ST1068 in cattle (15). Here, we also identified ST1068 in sheep C. coli (Figure 2) , which 463 had a similar PFGE pattern with cattle C. coli ( Figure S1b ). These findings further suggest the 464 possible transmission of FQ R C. coli (e.g. ST902 and ST1068) between cattle and sheep. In 465 contrast to the C. coli isolates, the predominant C. jejuni genotype ST2862 (Figure 3 ) in sheep 466 was not previously identified in cattle in the U.S. (15, 26, 58) . Although C. jejuni ST982 has 467 been found in cattle (15), their PFGE patterns were quite different from the sheep isolates 468 ( Figure S1c) . Thus, the genetic relatedness between sheep and cattle C. jejuni isolates were not 469 as clear as for C. coli. 470
In Campylobacter, FQ-resistance is mediated by point mutations in the QRDR of DNA 471 gyrase (GyrA) and the function of the CmeABC multidrug efflux pump (8, 61). The most 472 frequent mutation associated with FQ resistance in Campylobacter is Thr-86-Ile, followed by 473
Asp-90-Asn, Thr-86-Lys, Thr-86-Ala, Thr-86-Val, Asp-90-Tyr, and Ala-70-Thr (8, 62). 474
Additionally, double mutations including Thr-86-Ile/Pro-104-Ser and Thr-86-Ile/Asp-90-Asn 475 have also been associated with FQ resistance in Campylobacter (63). The mutation of Ser is also known to confer FQ resistance along with the Thr-86-Ile mutation (64). Ser-22-Gly 477 has not been linked to FQ resistance in Campylobacter and there was no evidence that on April 2, 2019 by guest http://aem.asm.org/ Downloaded from 22 Ser and Arg-285-Lys alone were associated with the FQ resistance phenotype (15) . In this study, 479 all examined FQ R Campylobacter isolates harbored the Thr-86-Ile mutation in GyrA, while one 480 isolate also carried the Ser-22-Gly, Asn-203-Ser and Arg-285-Lys mutations, consistent with the 481 known role of the Thr-86-Ile change (alone or along with other mutations) in CIP resistance. 482
In summary, we observed high prevalence of tetracycline-resistant Campylobacter and FQ R 483 C. coli in commercial sheep operations, regardless of in-feed medication with tetracycline. 484
Although the medication increased the total Campylobacter CFU counts in the sheep gallbladder, 485 it did not affect overall prevalence, genotypes, or antimicrobial susceptibility profiles of the 486
Campylobacter isolates under the conditions employed in this study. The sheep harbored 487 predominant genotypes of C. jejuni (ST2862) and C. coli (ST902). Of particular note, the FQ R C. 
